
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This study is looking at a drug called Reolysin in people with cancer that started in, or has spread to, the brain.
Reolysin is a cancer treatment made from a type of virus called reovirus. Reovirus is common and causes only minor symptoms such as cough, colds and diarrhoea. We know from research that Reolysin can kill cancer cells. But we do not yet know if it can reach, or affect, cancer cells in the brain.
Researchers in this study will recruit people who have a primary brain tumour that has come back or who have cancer that has spread to the brain, and are waiting for surgery to remove these tumours. Everyone taking part will have Reolysin before their surgery. The team will then look at brain tumour tissue removed during your surgery to see if the reovirus affected the cancer cells. They will also monitor how your immune system responds to the virus.
The aim of this study is to find out more about the effect of reovirus on brain tumours that have come back after treatment, or on cancer that has spread to the brain from another part of the body. You will not have any direct benefit from taking part in this study, but the results will be used to help people with cancer in the future.
You may be able to enter this study if
You cannot enter this study if you
This study will recruit 24 people into 3 groups. The group you join will depend on when you enter the study. Everyone taking part will have Reolysin before their planned brain surgery.
You have Reolysin through a drip into a vein. The study team will monitor your blood pressure, pulse and temperature before, during and up to an hour after you have the drug.
You fill out a diary card to record any side effects you may have such as cough, runny nose, diarrhoea or tummy pain. You will also give blood samples on the days you have Reolysin (if you are in group 1, you also give a blood sample on day 3 of the study), and before and after your surgery.
During the days you have Reolysin, and for 2 days afterwards, the team ask that you take the same precautions to protect others that you would if you had a cold or flu. This includes avoiding direct contact with people who have a severely compromised immune system. The team will give you some guidelines to follow for this.
Before you start the study, you will see the doctor and have some tests. These tests include
You visit the hospital each day you have Reolysin. If you are in group 1, you make an extra visit on day 3 to see the team and give another blood sample. So, depending on the group you are in, you could be making between 2 and 5 extra visits over the week.
Before your surgery and one month after surgery you have a physical examination and some blood tests. The team will pay for travel and car parking costs for visits directly related to this study.
Side effects of Reolysin include
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Alan Melcher
Professor Susan Short
Brain Tumour Research and Support across Yorkshire (BTRS)
Experimental Cancer Medicine Centre (ECMC)
Oncolytics Biotech Inc.
University of Leeds
Freephone 0808 800 4040
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.